Tobias Rausch

Integrated signatures define mutational processes in prostate cancer

Prostate cancer follows a long and heterogeneous disease course with incompletely understood aetiology. Here, we dissect the mutational processes shaping the genomes of 959 donors from the Pan Prostate Cancer Group (PPCG) and assess their clinical relevance. By integrating de nov...

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study

Abstract ASTRACT Background Prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT) demonstrates clinical efficacy in metastatic castration-resistant prostate cancer (mCRPC), yet robust biomarkers for dynamic treatment monitoring and resistance remain lacking....